14 pending office actions • 3 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Genentech, Inc. | 8 |
| Hoffmann-La Roche, Inc. | 4 |
| Hoffmann-La Roche, Inc. | 2 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Genentech, Inc. | SITTON, JEHANNE SOUAYA | 1682 | Non-Final OA | Jun 06, 2023 |
| 18326605 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES IN ELDERLY PATIENTS | Hoffmann-La Roche, Inc. | METCALF, MATTHEW CURRAN | 1647 | Non-Final OA | May 31, 2023 |
| 18326476 | BIOLOGICAL VESICLES DISPLAYING CELL SURFACE PROTEINS AND METHODS RELATED TO SAME | Genentech, Inc. | WEIDNER, ADAM M | 1675 | Non-Final OA | May 31, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | Genentech, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | Non-Final OA | May 26, 2023 |
| 18319406 | ANTI-CD3 ANTIBODIES AND METHODS OF USE | Genentech, Inc. | DRISCOLL, LORA E BARNHART | 3991 | Non-Final OA | May 17, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | Genentech, Inc. | NOAKES, SUZANNE MARIE | 1656 | Non-Final OA | Apr 28, 2023 |
| 18309582 | TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A TGFbeta SIGNALING INHIBITOR | Hoffmann-La Roche, Inc. | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Apr 28, 2023 |
| 18301180 | HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS | Hoffmann-La Roche, Inc. | DEBERRY, REGINA M | 1647 | Non-Final OA | Apr 14, 2023 |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Hoffmann-La Roche, Inc. | SAOUD, CHRISTINE J | 1645 | Non-Final OA | Apr 14, 2023 |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | Genentech, Inc. | ALLEN, MARIANNE P | 1647 | Non-Final OA | Apr 04, 2023 |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Hoffmann-La Roche, Inc. | CHATTIN, AMY MARIE | 1643 | Non-Final OA | Dec 15, 2022 |
| 18063459 | ANTIBODIES BINDING TO CD3 AND PLAP | Hoffmann-La Roche, Inc. | GUSTILO, ESTELLA M | 1646 | Non-Final OA | Dec 08, 2022 |
| 17937102 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | Genentech, Inc. | AEDER, SEAN E | 1642 | Non-Final OA | Sep 30, 2022 |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | Genentech, Inc. | CHASE, CAROL ANN | 1646 | Final Rejection | Sep 13, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial